Hepatitis C virus co-infection is a negative prognostic factor for clinical evolution in human immunodeficiency virus-positive patients.
A longitudinal study of human immunodeficiency virus (HIV)-infected individuals followed-up in 13 centres was performed to assess the influence of hepatitis C virus (HCV) on the clinical and immunological evolution of HIV-infected patients. Eight-hundred and twelve HIV-infected patients with known HIV acquisition date, 89 co-infected with HCV, were included in the cohort. Clinical progression was defined as: 30% decrease of Karnofsky's index; and/or 20% body weight loss; and/or acquired immune deficiency syndrome (AIDS)-defining illness; and/or death (except by accident, suicide, or overdose). Immunological progression was defined as a decrease of initial CD4 count to below 200 mm(-3). If immunological progression was not statistically different between groups (P=0.25), clinical progression was significantly faster in HCV-HIV co-infected patients in univariate (P=0.02) and multivariable survival analysis (hazard ratio=1.63, P=0.03). This argues for active management of hepatitis C chronic infection among HCV-HIV co-infected patients.
Piroth
L
L
The University Hospital of Dijon, France.
Grappin
M
M
Cuzin
L
L
Mouton
Y
Y
Bouchard
O
O
Raffi
F
F
Rey
D
D
Peyramond
D
D
Gourdon
F
F
Drobacheff
C
C
Lombart
M L
ML
Lucht
F
F
Besnier
J M
JM
Bernard
L
L
Chavanet
P
P
Portier
H
H
D000328:Adult; D018791:CD4 Lymphocyte Count; D015331:Cohort Studies; D005260:Female; D005602:France; D015658:HIV Infections / Q000150:complications* / Q000209:etiology / Q000276:immunology; D015497:HIV-1; D006526:Hepatitis C / Q000150:complications*; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D011379:Prognosis; D013997:Time Factors